{"id":45273,"date":"2022-06-20T18:01:52","date_gmt":"2022-06-20T16:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-vaccine-adjuvants-market-report-2022-to-2035-by-type-of-vaccine-adjuvant-route-of-administration-target-therapeutic-area-and-key-geographies-researchandmarkets-com\/"},"modified":"2022-06-20T18:01:52","modified_gmt":"2022-06-20T16:01:52","slug":"global-vaccine-adjuvants-market-report-2022-to-2035-by-type-of-vaccine-adjuvant-route-of-administration-target-therapeutic-area-and-key-geographies-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-vaccine-adjuvants-market-report-2022-to-2035-by-type-of-vaccine-adjuvant-route-of-administration-target-therapeutic-area-and-key-geographies-researchandmarkets-com\/","title":{"rendered":"Global Vaccine Adjuvants Market Report (2022 to 2035) – by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report features an extensive study of the current market landscape and future potential of the vaccine adjuvant market. The study features an in-depth analysis, highlighting the capabilities of vaccine adjuvant developers.\n<\/p>\n

\nAs per recent estimates (reported in May 2022), more than 11.6 billion doses of COVID-19 vaccines have been administered across 184 countries; this value roughly translates to 20.9 million doses per day. Vaccines have enabled the prevention of more than 37 million deaths due to various disease indications, such as cholera, diphtheria, influenza, tetanus, whooping cough and measles, between 2000 to 2019. Given the rate at which the global population is growing and taking into consideration the prevalent (such as the COVID-19 pandemic) and anticipated future trends, the demand for vaccines is likely to increase significantly.\n<\/p>\n

\nAccording to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. In this regard, significant strides have been made to develop safe and effective, next generation vaccine candidates, such as sub-unit vaccines, recombinant vaccines, conjugate vaccines and DNA vaccines.\n<\/p>\n

\nHowever, such vaccines employ purified non-living vaccine antigens (unlike their counterparts, live attenuated and inactivated vaccines) and are, most often, less immunogenic and require an additional aid to increase their immunogenicity against the target antigens. As a result, a variety of vaccine adjuvants (substances with the innate potential to augment an immune response), such as AS04 (Cervarix), MF59 (Fluad), AS01B (Shingrix) and CpG 1018 (Heplisav-B), have been discovered and are now available for the development of more effective and versatile vaccine formulations.\n<\/p>\n

\nPresently, an increasing number of vaccines under development are incorporating vaccine adjuvants owing to various advantages offered by such agents, including improved adaptive response to a vaccine, guiding the type of adaptive response to produce the most effective forms of immunity for each specific pathogen and facilitation of the use of smaller doses of antigen.\n<\/p>\n

\nFurther, majority of the adjuvants used in human vaccines enhance humoral immunity; however, several novel adjuvants in clinical or preclinical development are focused on enhancing specific types of T-cell responses to generate multifaceted immune responses required for complex indications, such as malaria and HIV-AIDS. Currently, more than 70 companies and academic \/ research institutes are engaged in the development of various types of vaccine adjuvants.\n<\/p>\n

\nIt is worth highlighting that capital investments worth over USD 5.5 billion have been made by various private and public sector investors during the last five years to fund the product development activity in this domain. In addition, there have been several recently reported instances of collaborations between industry \/ academic stakeholders to advance the development of various vaccine adjuvants. Driven by the increasing demand for safe and effective vaccines, ongoing pace of innovation in this field and financial support from the investors, the vaccine adjuvants market is likely to witness substantial growth in the mid to long-term.\n<\/p>\n

\nCompanies Mentioned<\/strong>\n<\/p>\n